0001437749-23-013652.txt : 20230510 0001437749-23-013652.hdr.sgml : 20230510 20230510164647 ACCESSION NUMBER: 0001437749-23-013652 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230510 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230510 DATE AS OF CHANGE: 20230510 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOLIFE SOLUTIONS INC CENTRAL INDEX KEY: 0000834365 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 943076866 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36362 FILM NUMBER: 23907301 BUSINESS ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 4254011400 MAIL ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: BIOLIFE SOLUTION INC DATE OF NAME CHANGE: 20030113 FORMER COMPANY: FORMER CONFORMED NAME: CRYOMEDICAL SCIENCES INC DATE OF NAME CHANGE: 19920703 8-K 1 bioli20230510_8k.htm FORM 8-K bioli20230510_8k.htm
false 0000834365 0000834365 2023-05-10 2023-05-10
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): May 10, 2023
 
BIOLIFE SOLUTIONS, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
  
001-36362
  
94-3076866
(State or other jurisdiction of
incorporation)
  
(Commission File Number)
  
(IRS Employer Identification No.)
 
3303 Monte Villa Parkway,
Bothell, WA 98021
(Address of principal executive offices) (Zip Code)
 
Registrant’s telephone number, including area code: (425) 402-1400
 
N/A
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading symbol
Name of exchange on which registered
BioLife Solutions, Inc. Common Stock
BLFS
NASDAQ Capital Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
 
 
Item 2.02         Results of Operations and Financial Condition.
 
On May 10, 2023, BioLife Solutions, Inc., a Delaware corporation, issued a press release announcing unaudited financial results and operational highlights for the first quarter ended March 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this current report on Form 8-K.
 
 
Item 9.01         Financial Statements and Exhibits.
 
(d) Exhibits
 
Exhibit No.
  
Description
99.1
  
104
  
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 
 
 
SIGNATURE
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
BioLife Solutions, Inc.
  
     
Date: May 10, 2023
By:
/s/ Troy Wichterman
  
   
Name: Troy Wichterman
Title: Chief Financial Officer
  
 
 
 EX-99.1 2 ex_518266.htm EXHIBIT 99.1 ex_518266.htm

Exhibit 99.1

 

letterhead.jpg

BioLife Solutions Reports First Quarter 2023 Financial Results

 

Revenue of $37.7 million increased 4% over Q1 2022, ex-COVID growth of 16% and biopreservation media revenue growth of 28%

 

Q1 2023 Adjusted gross margin improvement; 37% compared to 32% in Q4 2022

 

Decision to Explore Strategic Alternatives for Ultra-Low Temperature and Cryogenic Freezer Product Lines

 

Conference call begins at 4:30 p.m. Eastern time today

 

BOTHELL, Wash. (May 10, 2023) – BioLife Solutions, Inc. (Nasdaq: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and the broader biopharma markets, today announced financial results for the three months ended March 31, 2023.

 

Mike Rice, Chairman and CEO, commented, “In the first quarter of 2023, we continued to drive adoption of our Cell Processing, Storage and Storage Services, and Freezers and Thaw Systems platforms. We gained nearly 200 new customer sites across our portfolio and are now supporting a critical mass of customer clinical applications, with over 630 using our proprietary biopreservation media and nearly 140 using our Sexton cell processing tools. We gained 17 new evo® cold chain customers via our global courier network and have confirmation from a large global pharma company that following successful validation of evo, they plan to convert up to 100% of their shipments of two currently approved cell therapies from the incumbent to the evo platform.

 

Regarding our ULT and cryogenic freezer businesses, after thorough analysis and consultation with external advisors over the past few quarters, our management team, supported by our board of directors, has decided to explore strategic alternatives for CBS and Stirling, including potential divestitures. We are confident that refocusing our portfolio on high margin, high growth, recurring revenue streams is the right decision for BioLife and all of its stakeholders.”

 

First Quarter 2023 Customer Highlights

 

New Customer Acquisition

 

Platform/Solution

Q1 2023

Biopreservation Media

9

Sexton Cell Processing

8

SciSafe® Storage Services

22

Thaw

5

evo® Cold Chain

17

Cryogenic Freezers

15

ULT Freezers

121

TOTAL

197

 

 
letterhead.jpg
 

 

 

●

Gained nearly 200 new customers.
 

●

Processed 20 new USA Master File cross references for our cell processing solutions. Total global clinical applications with our cell processing solutions embedded are now estimated to be over 630 for biopreservation media and nearly 140 for Sexton products.
 

●

Cell processing tools are now included in 14 approved therapies.
 

●

evo cold chain management shipments of cell and gene therapies totaled 2,632 in Q1 2023, representing over 135% growth over Q1 2022.

 

First Quarter 2023 Operational Highlights

 

●

Biopreservation Media: Added second shift to increase capacity and support larger batch sizes. Re-building of finished goods buffer underway.
 

●

ULT Freezers: Negotiated cost reduction on sheet metal supply. Margin impact modest starting in Q3.
 

●

Cryogenic Freezers: Negotiated cost reduction on metals supply (coil and sheet). Margin impact modest starting in Q3.
 

●

Sexton Cell Processing: Continued progress on operations redundancy for Media Operations. Non-proprietary media products will be in full production in Q2, and proprietary media products planned for production in Q4.
 

●

Supply Chain: Finalized new shipping contract, savings expected in Q2 and beyond (greater than $300K annually).

 

First Quarter 2023 Financial Results

 

BioLife Solutions is presenting various financial metrics under U.S. Generally Accepted Accounting Principles (GAAP) and as adjusted (non-GAAP). A reconciliation of GAAP to non-GAAP metrics appears at the end of this news release.

 

REVENUE

 

 

●

Total revenue for the first quarter of 2023 was $37.7 million, an increase of $1.5 million, or 4%, from $36.2 million for the first quarter of 2022. There was no COVID-19 related revenue in the first quarter of 2023. Ex-COVID related revenue growth for the first quarter of 2023 was 16%.

 

 

o

Cell Processing platform revenue was $19.0 million, up $4.1 million, or 27%, over the same period in 2022. Biopreservation growth was 28%.

 

 

o

Freezers and Thaw Systems platform revenue was $13.0 million, down $2.3 million, or 15%, over the same period in 2022. Ex-COVID related revenue was down $1.8 million, or 12%, over the same period in 2022.

 

 

o

Storage and Storage Services platform revenue was $5.7 million, down $304,000, or 5%, over the same period in 2022. Ex-COVID related revenue growth was $2.8 million, or 98%, over the same period in 2022.

 

Page 2 of 12
letterhead.jpg

 

GROSS MARGIN

 

 

●

Gross margin (GAAP) for the first quarter of 2023 was 35% compared with 28% for the first quarter of 2022. Adjusted gross margin (non-GAAP) for the first quarter of 2023 was 37% compared with 33% for the first quarter of 2022.

 

 

●

The increase in gross margin and adjusted gross margin was primarily due to a favorable product mix in our biopreservation media product line and a greater concentration of higher margin revenue as a percentage of total revenue in comparison to Q1 2022.

 

OPERATING EXPENSE

 

 

●

Operating expense (GAAP) for the first quarter of 2023 was $51.3 million compared with $44.2 million for the first quarter of 2022. Adjusted operating expense (non-GAAP) for the first quarter of 2023 was $25.5 million compared with $20.1 million for the first quarter 2022.

 

 

●

The increase in GAAP and non-GAAP operating expenses for the first quarter of 2023 was primarily due to increases in professional services fees and employee compensation costs from an increase in headcount compared to the prior year.

 

OPERATING LOSS

 

 

●

Operating loss (GAAP) for the first quarter of 2023 was $13.6 million compared with $8.0 million for the first quarter of 2022. Adjusted operating loss (non-GAAP) for the first quarter of 2023 was $11.4 million compared with $8.3 million for the first quarter of 2022.

 

NET LOSS

 

 

●

Net loss (GAAP) for the first quarter of 2023 was $13.7 million compared with $7.4 million for the first quarter of 2022. Adjusted net loss (non-GAAP) for the first quarter of 2023 was $11.4 million compared with $8.4 million for the first quarter of 2022.

 

EARNINGS/(LOSS) PER SHARE

 

 

●

Loss per share (GAAP) for the first quarter of 2023 was $0.32 compared with loss per share of $0.18 for the first quarter of 2022.

 

ADJUSTED EBITDA

 

 

●

Adjusted EBITDA, a non-GAAP measure, for the first quarter of 2023 was negative $1.9 million compared with negative $1.1 million for the first quarter of 2022.

 

CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES

 

 

●

Cash, cash equivalents, and marketable securities as of March 31, 2023, were $56.9 million.

 

Page 3 of 12
letterhead.jpg

 

2023 Revenue Guidance

 

BioLife Solutions is reaffirming 2023 revenue guidance, which is based on expectations for its existing business.

 

Mike Rice, Chairman and CEO, further commented, “We fully expect to participate in the forecasted growth of the CGT industry over the next several years. Sustained catalysts that we expect to drive BioLife growth due to a significant increase in the number of manufactured doses include:

 

 

●

Approvals of new cell and gene therapies
 

●

Additional approvals of commercial CGT in new geographies
 

●

Additional approvals of CGT in new indications
 

●

Migration of commercial therapies to first or second-line treatment
 

●

An eventual transition to allogeneic therapies

 

We remain confident that we will achieve our Q4 2024 run rate aspirational financial goals of $250 million in revenue, 50 points of adjusted gross margin and 30 points of adjusted EBITDA.”

 

Total revenue for 2023 is expected to range from $188 million to $202 million, reflecting year-over-year growth of 16% to 25%. Excluding COVID-19-related revenue, this range reflects year-over-year growth of 26% to 35%.

 

Expectations for 2023 total revenue include the following platform contributions:

 

 

●

Cell processing platform: $89.0 million to $93.0 million, an increase of 30% to 35% over 2022.

 

 

●

Freezers and Thaw Systems platform: $72.5 million to $79.0 million, an increase of 9% to 18% over 2022. Excluding COVID-19-related revenue, year-over-year growth of 13% to 23%.

 

 

●

Storage and Storage Services platform: $26.5 million to $30.0 million, flat to an increase of 13% over 2022. Excluding COVID-19-related revenue, year-over-year growth of 64% to 86%.

 

Management expects gross margin and adjusted EBITDA expansion in 2023.

 

Page 4 of 12
letterhead.jpg

 

Conference Call & Webcast

 

Management will discuss the Company's financial results, provide a general business update and answer questions during a conference call and live webcast today at 4:30 p.m. ET (1:30 p.m. PT).

 

To access the webcast, log onto the Investor Relations page of the BioLife Solutions website at https://www.biolifesolutions.com/earnings. In addition, the conference call will be accessible by dialing toll-free (800) 715-9871 for domestic callers or (646) 307-1963 for international callers. The conference ID number is 4014878. A webcast replay will be available approximately two hours after the call ends and will be archived on https://www.biolifesolutions.com/ for 90 days.

 

Page 5 of 12
letterhead.jpg

 

About BioLife Solutions

 

BioLife Solutions is a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy and broader biopharma markets. Our tools portfolio includes our proprietary CryoStor® and HypoThermosol® biopreservation media for shipping and storage, the ThawSTAR® family of automated, water-free thawing products, evo® cold chain management system, high capacity cryogenic storage freezers, Stirling Ultracold mechanical freezers, SciSafe biologic storage services, and Sexton Biotechnologies cell processing tools. For more information, please visit www.biolifesolutions.com, www.scisafe.com, www.stirlingultracold.com, or www.sextonbio.com and follow BioLife on Twitter.

 

Cautions Regarding Forward Looking Statements

 

Except for historical information contained herein, this press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements concerning the expected financial performance of the Company, the Company's ability to implement its business strategy (including with respect to any strategic alternatives) and anticipated business and operations, the potential utility of and market for the Company's products and services, including, but not limited to, the adoption of the Company’s products for new clinical candidates in connection with expected clinical trials, and the Company’s ability to cross sell its products and services, guidance for financial results for 2023 and 2024, including regarding potential revenue growth and changes in product mix of total revenue and gross margin, the Company’s ability to realize reductions in expenses as a result reductions in supply and shipping costs, the Company's anticipated future growth strategy, including the acquisition of synergistic cell and gene therapy manufacturing tools and services or technologies, regulatory approvals and/or commercial manufacturing of our customers' products, and potential customer revenue. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, market adoption of the Company’s products, the ability of the Company to continue to implement its business strategy (including with respect to any strategic alternatives), uncertainty regarding third-party market projections, market volatility, competition, litigation, the impact of the COVID-19 pandemic and supply chain issues, unexpected costs, charges or expenses resulting from our acquisitions, and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

 

Non-GAAP Measures of Financial Performance:

 

To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included in this release: adjusted gross profit and gross margin, adjusted operating expenses, adjusted operating income/(loss), adjusted net income/(loss), earnings before interest, taxes, depreciation and amortization (EBITDA), and adjusted EBITDA. A reconciliation of GAAP to adjusted non-GAAP financial measures is included as an attachment to this press release. When analyzing the Company's operating results, investors should not consider non-GAAP measures as substitutes for the comparable financial measures prepared in accordance with GAAP.

 

Page 6 of 12
letterhead.jpg

 

Media & Investor Relations
 

At the Company
 
Troy Wichterman

Chief Financial Officer

(425) 402-1400

twichterman@biolifesolutions.com

 

 

Investors

 

LHA Investor Relations

Jody Cain

(310) 691-7100

jcain@lhai.com

 

Page 7 of 12
letterhead.jpg

 

BIOLIFE SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited, amounts in thousands, except share and per share amounts)

 

   

Three Months Ended

  
   

March 31,

 

(In thousands, except per share and share data)

  

2023

    

2022

  
                 

Product revenue

   $ 31,593     $ 30,388  

Service revenue

     4,471       3,090  

Rental revenue

     1,639       2,742  

Total revenue

     37,703       36,220  

Costs and operating expenses:

                

Cost of product, rental, and service revenue (exclusive of Intangible asset amortization)

     23,664       24,446  

Research and development

     4,152       3,781  

Sales and marketing

     6,471       4,891  

General and administrative

     14,842       11,530  

Intangible asset amortization

     1,459       2,863  

Acquisition costs

     -       11  

Change in fair value of contingent consideration

     720       (3,335 )

Total operating expenses

     51,308       44,187  

Operating loss

     (13,605 )     (7,967 )
                 

Other expense, net

                

Interest expense, net

     (411 )     (184 )

Other income

     394       131  

Total other expense

     (17 )     (53 )
                 

Loss before income tax (expense) benefit

     (13,622 )     (8,020 )

Income tax (expense) benefit

     (92 )     599  

Net loss

   $ (13,714 )   $ (7,421 )
                 

Net loss attributable to common shareholders

                

Basic and Diluted

   $ (0.32 )   $ (0.18 )

Weighted average shares used to compute loss per share attributable to common shareholders:

                

Basic and Diluted

     43,027,612       42,014,055  

 

Page 8 of 12
letterhead.jpg

 

BIOLIFE SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(Unaudited, amounts in thousands, except per share amounts)

 

   

Three Months Ended

  
   

March 31,

 

(In thousands)

  

2023

    

2022

  
                 

NET LOSS

   $ (13,714 )   $ (7,421 )

Other comprehensive income/(loss)

     145       (156 )

COMPREHENSIVE LOSS

   $ (13,569 )   $ (7,577 )

 

 

BIOLIFE SOLUTIONS, INC.

CONDENSED CONSOLIDATED BALANCE SHEET INFORMATION

(Unaudited, amounts in thousands)

 

   

March 31,

   

December 31,

  

(In thousands)

  

2023

    

2022

  

Cash, cash equivalents, and marketable securities

   $ 56,935     $ 64,065  

Working capital

     85,470       93,870  

Current assets

     132,789       138,452  

Current liabilities

     47,319       44,582  

Total assets

     446,470       450,229  
                 

Long-term obligations

     41,044       41,459  

Accumulated deficit

     (260,629 )     (246,915 )

Total shareholders' equity

   $ 358,107     $ 364,188  

 

 

BIOLIFE SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS INFORMATION

(Unaudited, amounts in thousands)

 

   

Three Months Ended

  
   

March 31,

 

(In thousands)

  

2023

    

2022

  

Net cash used in operating activities

   $ (2,712 )   $ (7,924 )

Net cash provided by (used in) investing activities

     2,926       (2,270 )

Net cash used in financing activities

     (562 )     (181 )

Effects of currency translation

     11       (22 )

Net decrease in cash, cash equivalents and restricted stock

   $ (337 )   $ (10,397 )

 

Page 9 of 12
letterhead.jpg

 

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP GROSS PROFIT TO NON-GAAP (ADJUSTED) GROSS PROFIT

(Unaudited, amounts in thousands)

 

   

Three Months Ended

  
   

March 31,

 

(In thousands)

  

2023

    

2022

  

GAAP GROSS PROFIT

   $ 13,306     $ 10,285  

GAAP GROSS MARGIN

     35

%

     28

%
                 

ADJUSTMENTS TO GROSS PROFIT:

                

Intangible asset amortization

     733       1,489  

ADJUSTED GROSS PROFIT

   $ 14,039     $ 11,774  

ADJUSTED GROSS MARGIN

     37

%

     33

%

 

 

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP OPERATING EXPENSES TO NON-GAAP (ADJUSTED) OPERATING EXPENSES

(Unaudited, amounts in thousands)

 

   

Three Months Ended

  
   

March 31,

 

(In thousands)

  

2023

    

2022

  

GAAP OPERATING EXPENSES

   $ 51,308     $ 44,187  
                 

ADJUSTMENTS TO OPERATING EXPENSES:

                

Cost of product, rental, and service revenue

     (23,664 )     (24,446 )

Acquisition costs

     -       (11 )

Intangible asset amortization

     (1,459 )     (2,863 )

Loss on disposal of assets

     (9 )     (96 )

Change in fair value of contingent consideration

     (720 )     3,335  

ADJUSTED OPERATING EXPENSES

   $ 25,456     $ 20,106  

 

 

Page 10 of 12
letterhead.jpg

 

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP OPERATING INCOME (LOSS) TO NON-GAAP (ADJUSTED) OPERATING INCOME (LOSS)

(Unaudited, amounts in thousands)

 

   

Three Months Ended

  
   

March 31,

 

(In thousands)

  

2023

    

2022

  

GAAP OPERATING LOSS

   $ (13,605 )   $ (7,967 )
                 

ADJUSTMENTS TO OPERATING LOSS:

                

Acquisition costs

     -       11  

Intangible asset amortization

     1,459       2,863  

Loss on disposal of assets

     9       96  

Change in fair value of contingent consideration

     720       (3,335 )

ADJUSTED OPERATING LOSS

   $ (11,417 )   $ (8,332 )

 

 

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP NET INCOME (LOSS) TO NON-GAAP (ADJUSTED) NET INCOME (LOSS)

(Unaudited, amounts in thousands)

 

   

Three Months Ended

  
   

March 31,

 

(In thousands)

  

2023

    

2022

  

GAAP NET LOSS

   $ (13,714 )   $ (7,421 )
                 

ADJUSTMENTS TO NET LOSS:

                

Acquisition costs

     -       11  

Intangible asset amortization

     1,459       2,863  

Loss on disposal of assets

     9       96  

Change in fair value of contingent consideration

     720       (3,335 )

Income tax benefit

     92       (599 )

ADJUSTED NET LOSS

   $ (11,434 )   $ (8,385 )

 

Page 11 of 12
letterhead.jpg

 

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP NET INCOME (LOSS) TO NON-GAAP (ADJUSTED) EBITDA

(Unaudited, amounts in thousands)

 

   

Three Months Ended

  
   

March 31,

 

(In thousands)

  

2023

    

2022

  

GAAP NET LOSS

   $ (13,714 )   $ (7,421 )
                 

ADJUSTMENTS:

                

Interest expense, net

     411       184  

Income tax expense (benefit)

     92       (599 )

Depreciation

     1,731       1,653  

Intangible asset amortization

     1,459       2,863  

EBITDA

   $ (10,021 )   $ (3,320 )
                 

OTHER ADJUSTMENTS:

                

Share-based compensation (non-cash)

     7,363       5,399  

Acquisition costs

     -       11  

Loss on disposal of assets

     9       96  

Change in fair value of contingent consideration

     720       (3,335 )

ADJUSTED EBITDA

   $ (1,929 )   $ (1,149 )

 

# # #

Page 12 of 12
 EX-101.SCH 3 blfs-20230510.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 blfs-20230510_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 blfs-20230510_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Emerging Growth Company Amendment Flag Entity, Central Index Key EX-101.PRE 6 blfs-20230510_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 letterhead.jpg begin 644 letterhead.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document And Entity Information
May 10, 2023
Document Information [Line Items]  
Entity, Registrant Name BIOLIFE SOLUTIONS, INC.
Document, Type 8-K
Document, Period End Date May 10, 2023
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-36362
Entity, Tax Identification Number 94-3076866
Entity, Address, Address Line One 3303 Monte Villa Parkway
Entity, Address, City or Town Bothell
Entity, Address, State or Province WA
Entity, Address, Postal Zip Code 98021
City Area Code 425
Local Phone Number 402-1400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security BioLife Solutions, Inc. Common Stock
Trading Symbol BLFS
Security Exchange Name NASDAQ
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0000834365
XML 9 bioli20230510_8k_htm.xml IDEA: XBRL DOCUMENT 0000834365 2023-05-10 2023-05-10 false 0000834365 8-K 2023-05-10 BIOLIFE SOLUTIONS, INC. DE 001-36362 94-3076866 3303 Monte Villa Parkway Bothell WA 98021 425 402-1400 false false false false BioLife Solutions, Inc. Common Stock BLFS NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 22 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.blfs.com/20230510/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports bioli20230510_8k.htm blfs-20230510.xsd blfs-20230510_def.xml blfs-20230510_lab.xml blfs-20230510_pre.xml ex_518266.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bioli20230510_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 22 }, "contextCount": 1, "dts": { "definitionLink": { "local": [ "blfs-20230510_def.xml" ] }, "inline": { "local": [ "bioli20230510_8k.htm" ] }, "labelLink": { "local": [ "blfs-20230510_lab.xml" ] }, "presentationLink": { "local": [ "blfs-20230510_pre.xml" ] }, "schema": { "local": [ "blfs-20230510.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 26, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "blfs", "nsuri": "http://www.blfs.com/20230510", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bioli20230510_8k.htm", "contextRef": "d20238K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.blfs.com/20230510/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bioli20230510_8k.htm", "contextRef": "d20238K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230510/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230510/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230510/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document, Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230510/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document, Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230510/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity, Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230510/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity, Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230510/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity, Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230510/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity, Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230510/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity, Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230510/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230510/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity, Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230510/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity, File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230510/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity, Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230510/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity, Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230510/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity, Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230510/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230510/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230510/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230510/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230510/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230510/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230510/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230510/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230510/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230510/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001437749-23-013652-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-23-013652-xbrl.zip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�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end